Skip to main content

Advertisement

Table 4 Results of immunohistochemical stainings

From: Presence of HER4 associates with increased sensitivity to Herceptin™ in patients with metastatic breast cancer

Scoring HER1 (n = 48) HER3 (n = 47) HER4 (n = 48) phospho-HER2 (n = 43) p27Kip1 (n = 48) ERα (n = 45) PR (n = 46)
0 37 (77.1) 8 (16.7) 22 (45.8) 36 (83.7) n/a n/a n/a
1 7 (14.6) 31 (64.6) 7 (14.6) 3 (7.0) n/a n/a n/a
2 3 (6.2) 8 (16.7) 12 (25.0) 4 (9.3) n/a n/a n/a
3 1 (2.1) 0 7 (14.6) 0 n/a n/a n/a
Negative 37 (77.1) 8 (16.7) 22 (45.8) 36 (83.7) 24 (50.0) 19 (42.2) 29 (63.0)
Positive 11 (22.9) 39 (81.2) 26 (54.2) 7 (16.3) 24 (50.0) 26 (57.8) 17 (37.0)
  1. All 48 patients were HER2 FISH positive (ratio > 1.5). Numbers in parentheses are percentages. Results in bold define data considered positive for immunohistochemistry. n/a = not applicable, scoring defined in methodical chapter.
  2. ER = oestrogen receptor; HER = human epidermal growth factor receptor; PR = Progesterone receptor.